Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.62% | 0.90% | -8.46% | -13.36% | -30.19% |
| Total Depreciation and Amortization | 8.76% | 90.96% | 63.41% | 36.13% | 9.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.21% | 684.50% | -36.95% | -55.59% | -39.10% |
| Change in Net Operating Assets | -71.49% | -38.27% | -55.92% | -94.28% | 314.16% |
| Cash from Operations | 11.99% | 2.15% | -17.11% | -39.99% | -24.16% |
| Capital Expenditure | 85.71% | 66.44% | 55.49% | 4.13% | 32.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 227.00% | 8,304.92% | 4,417.87% | 1,497.82% | 471.07% |
| Cash from Investing | 228.17% | 8,995.57% | 4,153.29% | 1,463.43% | 462.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,355.77% | 1,356.97% | -78.06% | -78.06% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,146.33% | 324.28% | 102.69% | 102.69% | 113.34% |
| Foreign Exchange rate Adjustments | 167.47% | -385.27% | -30.97% | -11.14% | -74.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 78.59% | 101.64% | 56.75% | 18.29% | 8.72% |